Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients
NCT02965417
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Stopped
Symphogen made a business decision to no longer perform the clinical study.
Conditions
Metastatic Colorectal Cancer
Interventions
DRUG:
Sym004
Sponsor
Symphogen A/S